B Cells--Tumors clinical trials at UCSF

• Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

  open to eligible people ages 18 years and up

  First-in-human Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-001 given intravenously every 3 weeks.

  San Francisco, California and other locations

Last updated: October 14, 2020